Walgreen's stock has been taken to the cleaners this week. While quarterly revenue rose by more than 10 percent to $13.4 billion, the company's profit slid by 4% year over year to $396.5 million or 40 cents per share. Analysts who had expected earnings over 47 cents a share and revenue of $13.5 billion let the company have it.
The company improved its top line greatly but missed on the bottom line as a result of the growing use of simvastatin, a generic version of the popular cholesterol-lowering drug Zocor. From looking at Walgreen's report, it is clear that reimbursement rates from insurance plans have fallen since the generic medication came on the market last summer. It is also clear that Walgreen's filled three times the number of simvastatin prescriptions during the fourth quarter as it did during the same period last year but made the same amount of money selling the drug.
I think Walgreen's is buy here at 39 on valuation alone at less than 20x current earnings. But, this has me wondering whether I should sell my stock in Pfizer, Merck, Schering and Astra given that these companies derive so much of their revenue from cholestorol lowering drugs. I am also concerned about the risks to statins that Pharmaking has written about on this site. These types of health risks may be ignored by the media, but they never go away. I enjoy Pharmaking's articles and would be interested in knowing what he thinks.
Related Articles:
Vioxx\'s Cardiac risk starts early by pharmaking - Jul 03, 2007
Profile of Steve Nissen-Public Enemy #1 of Big Pharma by pharmaking - Jul 21, 2007
Media Completely Ignores Statin - Cancer Connect by pharmaking - Jul 26, 2007
Pfizer Reaffirms Guidance by JRubinstein - Jul 18, 2007
PFE, GSK, LLY should pop on bad suicide data for kids by walt - Sep 06, 2007
Zetia and Vytorin- Where's the beef by pharmaking - Dec 02, 2007
Congress to investigate Zetia by pharmaking - Dec 12, 2007
Merck and Schering are screaming shorts again by pharmaking - Apr 09, 2008.
Add to reading list
